Merck and Pfizer claim second FDA nod for cancer drug Bavencio

Merck KGaA and Pfizer's immuno-oncology drug Bavencio has been approved by the FDA for bladder cancer, the second for the new drug in less than two months. ... Also in the offing is Merck &Co's PD-1 inhibitor Keytruda (pembrolizumab) which has been filed

Merck takes on Roche with first-line bladder OK for Keytruda

Merck takes on Roche with first-line bladder OK for Keytruda. FDA awards accelerated approval for mUC patients. ... Keytruda joins Roche's Tecentriq (atezolizumab) in the first-line UC treatment setting, and Tecentriq and three other checkpoint

IFPMA appoints Fumie Griego as assistant director general

IFPMA appoints Fumie Griego as assistant director general. She joins the global pharma association from Merck KGaA. ... She joins from Merck KGaA, where she held senior roles such as head of global oncology policy and strategy, global government affairs

Tecentriq bladder cancer approval in doubt after trial failure

Now, Roche is facing the possibility that its conditional approval could be revoked at a time when other drugs in the class - BMS' Opdivo (nivolumab), Merck KGaA/Pfizer's Bavencio (avelumab), ... AstraZeneca's Imfinzi (durvalumab) - have already claimed

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 (Next 5)